


Fig. 1



CONTINUOUS PHASE
WATER
SODIUM CHOLATE
BENZYL ALCOHOL
DISPERSED PHASE
POLYMERS *
DASATINIB / TFA
ETHYL ACETATE
BENZYL ALCOHOL
SOLUTION PREPARATION
*POLYMERS INCLUDE PLGA-PEG, PLGA, PLA-PEG, PLA, AND PLA-PEG-LIGAND
COARSE EMULSION
HIGH ENERGY EMULSIFICATION (HIGH PRESSURE HOMOGENIZER)
EMULSIFICATION
FINE EMULSION
QUENCH SOLUTION
COLD WATER
TWEEN 80
PARTICLE QUENCH
QUENCH
HARDENED PARTICLES
COLD WATER
TANGENTIAL FLOW FILTRATION
ULTRAFILTRATION/ DIAFILTRATION
PURIFIED PARTICLES
STERILE FILTRATION
FILTRATION
STERILE PARTICLES
WATER SUCROSE
FINAL PARTICLE SUSPENSION
FINAL FORMULATION
VIALS FOR FREEZING OR LYOPHILIZATION

Fig. 2



AQUEOUS PHASE
(1) ADD WATER PHASE AND START AGITATION
ORGANIC PHASE
(2) ADD OIL PHASE UNDER HIGH SHEAR AGITATION
HIGH SHEAR MIXER
COARSE EMULSION VESSEL
(3) CREATE FINE EMULSION
HIGH PRESSURE HOMOGENIZER
(4) TRANSFER TO QUENCH VESSEL
(5) ADD DRUG SOLUBILIZER
QUENCH TANK
JACKET OUTLET
JACKET INLET
(6) TO DOWNSTREAM PROCESSING

Fig. 3A



1) CONCENTRATE FROM ~10 TO ~30 mg/ml
2) 5X COLD DIAFILTRATION (99% REDUCTION IN SOLUTES)
3) WARM TO 25C AND ADD ADDITIONAL DRUG SOLUBILIZER
4) ADDITIONAL 15X DIAFILTRATION (99.99% REDUCTION IN SOLUTES)
5) CONCENTRATE FROM ~30 mg/ml TO ~100 mg/ml
6) COLLECT FINAL CONCENTRATED SLURRY
TO FILTRATION TRAIN
FILTRATE TO WASTE
RETENTATE
TFF
PUMP
QUENCH TANK
DIAFILTRATE (DI WATER)

Fig. 3B



170-51-2, FINE 16/5, 10% SOLID, 5% TARGET LOAD, BA ONLY, 106.4nm, 0.98%
170-51-1, CRUDE 16/5, 10% SOLID, 5% TARGET LOAD, BA ONLY, 113.3nm, 0.87%
170-65-3, CRUDE 16/5, 4.7% SOLID, 10% TARGET LOAD, 6% OLEIC ACID, 20/80 BA/EA, 113.6nm, 0.54%
170-65-1, CRUDE 16/5, 4.7% SOLID, 30% TARGET LOAD, 1% TFA, 20/80 BA/EA, 137.2nm, 0.34%
170-65-2, CRUDE 16/5, 4.7% SOLID, 30% TARGET LOAD, 3% TFA, 20/80 BA/EA, 143.1nm, 2.54%
170-51-3, 47/5, 10% SOLID, 5% TARGET LOAD, BA ONLY, 112.9nm, 0.46%
CUMULATIVE RELEASE (%)
0
10
20
30
40
50
60
70
80
TIME (HOURS)
0
1
2
3
4
5

FIG. 4